Data suggests that many people who use GLP-1 drugs semaglutide and liraglutide to treat obesity and diabetes are not staying on their weight-loss plans as long as what is recommended, according to an issue brief from Blue Health Intelligence. Typically, 12 weeks is the accepted guideline for achieving meaningful weight loss. Yet, an analysis of claims from 170,000 plan members found that about 58% of people using GLP-1 medications were on their treatment plan for …
Read More